Eurocor - Life Sciences Technologies Interventional Cardiology Devices Endovascular Therapies

Dediacted to Your heart.
Life Sciences Technology.
Coronary stent technologies and special cardiovascular and endovascluar devices made in Europe for the world.

Eurocor GmbH announces Study results of Valentines Trial I

Date: 2011/03/04

DIOR® shows effective and safe treatment for cases of In-Stent Restenosis (ISR)
Database with larges group of patients ever enrolled to show effectiveness of DEB in treatmen of ISR

Eurocor GmbH, the Bonn-based subsidiary of Opto Circuits (India) Ltd; presented the first eight month follow-up data from the Valentines Trial I Global Registry on March 1st 2011 during the CRT 2011 Meeting. Eurocor's groundbreaking Valentines Trial I was conducted with an objective to assess the efficacy of the paclitaxel-eluting balloon Dior®- II far In-stent Restenosis (ISR) following Bare Metal Stent (BMS) and Drug-eluting Stent (DES) implantation at 6-9 months. 300 patients (those suffering from ISR) were enrolled by 96 Investigators from 26 countries starting 14th February 2010 in aperiod of 9 days and the initial eight-month foIlow-up data was announced Tuesday by principal investigator Prof. Dr. Sigmund Silber of Munich, Germany during the Conference. This landmark clinical study represents the largest group of patients ever enrolled in a study on the effectiveness of DEB in the treatment of ISR.

Eurocor GmbH announces Study results of Valentines Trial I (English)

Eurocor GmbH veröffentlich Studienergebnisse zu Valentines Trial I (Deutsch)